


DESCRIPTION	
Species Reactivity	Human/Primate
Specificity	Detects human ST2/IL-33 R in ELISAs and Western blots. In Western blots, no cross-reactivity with recombinant mouse ST2L, recombinant human (rh) IL-1 RI, rhIL-1 RII, rhIL-1 RA, rhIL-1 α , or rhIL-1 β is observed.
Source	Monoclonal Mouse IgG ₁ Clone # 97203
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	S. frugiperda insect ovarian cell line Sf 21-derived recombinant human ST2/IL-33 R Lys19-Phe328 Accession # BAA02233
Endotoxin Level	<0.10 EU per 1 μ g of the antibody by the LAL method.
Formulation	Lyophilized from a 0.2 μ m filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 μ m filtered solution in PBS.

APPLICATIONS	
Please Note: Optimal dilutions should be determined by each laboratory for each application. <i>General Protocols</i> are available in the <i>Technical Information</i> section on our website.	
	Recommended Concentration
Western Blot	1 μ g/mL
Human/Primate ST2/IL-33 R Sandwich Immunoassay	Sample Recombinant Human ST2/IL-1 R4 Fc Chimera (Catalog # 523-ST)
ELISA Capture	2-8 μ g/mL
ELISA Detection	Reagent Human/Primate ST2/IL-33 R Antibody (Catalog # MAB523)
Standard	0.1-0.4 μ g/mL
Neutralization	Human/Primate ST2/IL-33 R Biotinylated Antibody (Catalog # BAF523) Recombinant Human ST2/IL-33 R Fc Chimera (Catalog # 523-ST)
	Measured by its ability to neutralize IL-33-induced IFN- γ secretion in Human Peripheral Blood Mononuclear cells (PBMC). The Neutralization Dose (ND ₅₀) is typically 0.3-1.5 μ g/mL in the presence of 1 ng/mL Recombinant Human IL-33.



PREPARATION AND STORAGE	
Reconstitution	Reconstitute at 0.5 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

ST2, also known as IL-1 R4 and T1, is an Interleukin-1 receptor family glycoprotein that contributes to Th2 immune responses (1, 2). Human ST2 consists of a 310 amino acid (aa) extracellular domain (ECD) with three Ig-like domains, a 21 aa transmembrane segment, and a 207 aa cytoplasmic domain with an intracellular TIR domain (3, 4). Alternate splicing of the 120 kDa human ST2 generates a soluble 60 kDa isoform that lacks the transmembrane and cytoplasmic regions as well as an isoform that additionally lacks the third Ig-like domain (4). Within the ECD, human ST2 shares 68% and 64% aa sequence identity with mouse and rat ST2, respectively. ST2 is expressed on the surface of mast cells, activated Th2 cells, macrophages, and cardiac myocytes (5-8). It binds IL-33, a cytokine that is upregulated by inflammation or mechanical strain in smooth muscle cells, airway epithelia, keratinocytes, and cardiac fibroblasts (5, 9). IL-33 binding induces the association of ST2 with IL-1R AcP, a shared signaling subunit that also associates with IL-1 RI and IL-1 R rp2 (1, 10, 11). In macrophages, ST2 interferes with signaling from IL-1 RI and TLR4 by sequestering the adaptor proteins MyD88 and Mal (7). In addition to its role in promoting mast cell and Th2 dependent inflammation, ST2 activation enhances antigen induced hypernociception and protects from atherosclerosis and cardiac hypertrophy (5, 12-14). The soluble ST2 isoform is released by activated Th2 cells and strained cardiac myocytes and is elevated in the serum in allergic asthma (6, 8, 15). Soluble ST2 functions as a decoy receptor that blocks the ability of IL-33 to signal through transmembrane ST2 (10, 13-15).

References:

1. Barksby, H.E. *et al.* (2007) *Clin. Exp. Immunol.* **149**:217.
2. Gadina, M. and C.A. Jefferies (2007) *Science STKE* **2007**:pe31.
3. Tominaga, S. *et al.* (1992) *Biochim. Biophys. Acta* **1171**:215.
4. Li, H. *et al.* (2000) *Genomics* **67**:284.
5. Schmitz, J. *et al.* (2005) *Immunity* **23**:479.
6. Lecart, S. *et al.* (2002) *Eur. J. Immunol.* **32**:2979.
7. Brint, E.K. *et al.* (2004) *Nat. Immunol.* **5**:373.
8. Weinberg, E.O. *et al.* (2002) *Circulation* **106**:2961.
9. Sanada S. *et al.* (2007) *J. Clin. Invest.* **117**:1538.
10. Palmer, G. *et al.* (2008) *Cytokine* **42**:358.
11. Chackerian, A.A. *et al.* (2007) *J. Immunol.* **179**:2551.
12. Allakhverdi, Z. *et al.* (2007) *J. Immunol.* **179**:2051.
13. Verri Jr., W.A. *et al.* (2008) *Proc. Natl. Acad. Sci.* **105**:2723.
14. Miller, A.M. *et al.* (2008) *J. Exp. Med.* **205**:339.
15. Hayakawa, H. *et al.* (2007) *J. Biol. Chem.* **282**:26369.